MarginsXMarginsX
Home › Data Desk › Ovid Therapeutics Inc. has about 2.9 months of cash at its recent burn

MarginsX Data Desk · Quarterly results · Early-stage clinical trials · Late-stage clinical trials · Licensing and milestone payments

Ovid Therapeutics Inc. has about 2.9 months of cash at its recent burn

The 10-Q that Ovid Therapeutics Inc. (OVID) filed on Nov 10, 2026 covers the quarter ended Sep 30, 2026. (SEC XBRL company facts, 10-Q, Nov 10, 2026)

By the MarginsX Data Desk, automated. Published November 14, 2026. Data as of November 10, 2026.

Line chart of Ovid Therapeutics Inc. (OVID) daily closes from Jul 6, 2026 to Nov 10, 2026, with the results filing on Nov 10, 2026 marked.

Revenue and margins

Revenue was $0. (SEC XBRL company facts, 10-Q, Nov 10, 2026)

The net loss was $20.8M. (SEC XBRL company facts, 10-Q, Nov 10, 2026)

Balance sheet

Cash was $13.8M at Sep 30, 2026, against $11.3M at Jun 30, 2026. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)

Shares outstanding were 188.7 million, against 195.3 million at Jun 30, 2026, a fall of 3.4%. (SEC XBRL company facts, 10-Q, Nov 10, 2026)

At its recent quarterly burn of $14.4M, that cash lasts about 2.9 months, by our estimate from its XBRL cash flows. (Company health, computed by us from SEC filings and XBRL, Sep 30, 2026)

The stock

The Nasdaq screener puts its market value at $481.3M. (Nasdaq stock screener, Nov 13, 2026)

Ovid Therapeutics Inc. puts an S-3 shelf registration on file

On Nov 10, 2026, Ovid Therapeutics Inc. (OVID) filed an S-3: a shelf registration for securities it can sell later. (SEC EDGAR, S-3, Nov 10, 2026)

Follow it up

The company's page on MarginsX, with its filings, health check and ownership. (capital.sophiaxt.com/stocks/OVID)

The filing on SEC EDGAR. (sec.gov)

The filing in the MarginsX reader. (MarginsX reader)

Automated from SEC filings and market data by the MarginsX Data Desk, written by template with no AI. For information only. Not investment advice.

Facts behind this article

FactValueSourceAs of
NameOvid Therapeutics Inc.Source2026-11-13
Runway2.9 monthsSource2026-09-30
Form10-QSource2026-11-10
WhoOvid Therapeutics Inc. (OVID)Source2026-11-13
SymbolOVIDSource2026-11-13
FiledNov 10, 2026Source2026-11-10
Period endSep 30, 2026Source2026-11-10
Revenue0 USDSource2026-11-10
Net loss20,780,000 USDSource2026-11-10
Net income-20,780,000 USDSource2026-11-10
Cash13,811,000 USDSource2026-09-30
Cash prior11,327,000 USDSource2026-08-13
Prior endJun 30, 2026Source2026-08-13
Shares188,731,914 sharesSource2026-11-10
Shares prior195,297,857 sharesSource2026-08-13
Dilution-0.034 %Source2026-11-10
Burn abs14,444,500 USDSource2026-09-30
Burn-14,444,500 USDSource2026-09-30
Cap481,266,381 USDSource2026-11-13
FormS-3Source2026-11-10

Sources

Automated from SEC filings and market data. No AI. For information only. Not investment advice.

Discuss in MarginsX More from the Data Desk

More on MarginsX

Companies in this article

Topics

Related Data Desk stories

Every Data Desk article: /desk · RSS